Published in final edited form as:

Tetrahedron Lett. 2009 June 24; 50(25): 3074–3076. doi:10.1016/j.tetlet.2009.04.021.

A facile synthesis of bispyrroloquinone and bispyrroloiminoquinone ring system of marine alkaloids

Srinivasan Murugesan, Dwayaja H. Nadkarni, and Sadanandan E. Velu*

Department of Chemistry, University of Alabama at Birmingham, 901 14th Street South, Birmingham, Alabama 35294, USA

Abstract

Bispyrroloquinone and bispyrroloiminoquinone are two important polycyclic ring systems present in biologically active marine alkaloids such as Zyzzyanones, tsitsikammamines and wakayin. A facile synthesis of these two ring systems starting from a 6-benzylamino indole-4,7-quinone or 6-benzylamino pyrroloiminoquinone is described here. This chemistry involves the construction of a pyrrole ring in a single step by treatment of the starting reagents with ethyl acetoacetate or phenylbutane-1,3-dione in the presence of ceric ammonium nitrate in MeOH/CH₂Cl₂ solvent.

As a result of the potential for drug discovery, marine natural products have attracted the attention of scientists from various disciplines. Pharmacological value of the marine alkaloids is illustrated by the fact that about a dozen of marine alkaloids are currently undergoing various phases of human clinical trials for treatment of different cancers ^{1–3}. The largest number of bioactive marine alkaloids with novel structures have been isolated from marine sponges ^{4,5}. Sponges produce a plethora of chemical compounds with widely varying carbon skeletons. Most bioactive compounds from sponges have exhibited a variety of activities such as anti-inflammatory, antitumor, immunosuppressive, neurosuppressive, antiviral, antimalarial and antibiotic activities. While a number of these alkaloids have been isolated in quantities sufficient to ascertain their biological profile, many with unique structures are available only in minute quantities, precluding their thorough biological evaluations. Laboratory synthesis of these alkaloids and their analogues is the only practical way to access these materials in larger quantities.

Marine sponges of the genera *Latrunculia*, *Batzella*, *Prianos* and *Zyzya* are a rich source of alkaloids bearing a pyrrolo[4,3,2-*de*]quinoline skeleton ^{6,7}. This series of alkaloids comprise of about 60 metabolites including discorhabdins ⁸, epinardins ⁹, batzellines ¹⁰, isobatzellines ¹⁰, makaluvamines ^{11–16}, veitamine ¹⁷, wakayin ¹⁸ and tsitsikammamines ^{19,20}.

© 2009 Elsevier Science. All rights reserved.

*Corresponding author: Tel.: +1-205-975-2478; fax: +1-205-934-2543; svelu@uab.edu.

Supplementary data

The supplementary data for this paper is available online at ScienceDirect

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Pyrrolo[4,3,2-*de*]quinoline alkaloids have shown a variety of biological activities such as inhibition of topoisomerase I¹¹ and II,¹⁴ cytotoxicity against different tumor cell lines,^{21,14} antifungal¹¹ and antimicrobial activities²². Pyrrolo[4,3,2-*de*]quinoline alkaloids have recently received increasing attention as a source of new anticancer drugs^{23–28}. Their unique fused ring skeletons carrying interesting biological properties have made them targets for several synthetic and biological studies. There has been a rapid growth of interest in the synthesis and biological evaluation of this class of compounds and their analogues. Several reviews have been published on the chemistry and bioactivity of this class of compounds^{6,29–31}.

Of these alkaloids, wakayin and tsitsikammamines possess a unique tetracyclic bispyrroloiminoquinone ring system (Figure 1). Wakayin was isolated by Ireland et al in 1991 from an ascidian of *Clavelina* species¹⁸. It has exhibited cytotoxic properties and inhibition of topoisomerase I. Several aza analogs of these alkaloids reported recently have shown inhibition of both topoisomerase I and II. Tsitsikammamines A and B were isolated from four new species of South African latrunculid sponges namely, *Tsitsikamma pedunculata*, *T. favus*, *Latrunculia bellae*, and *Strongylodesma algoensis*^{19,20}. They do exhibit cytotoxic properties, but do not inhibit either topoisomerases I or II. A related class of tricyclic bispyrroloquinone alkaloids called Zyzzyanones A-D (Fig. 1) has been isolated recently from the Australian marine sponge *Zyzya fuliginosa*^{32,33}.

Because of their potent biological activities and unique structural features several attempts were made towards the synthesis of these alkaloids and the unique ring system present in these alkaloids^{34,35}. While there is a very recent report of total synthesis of tsitsikammamine A³⁶, there are several other reports available on the synthesis and biological evaluation of the analogs of these alkaloids are available^{37,26,27,38}.

As a part of our work on the synthesis and biological evaluation of analogs of marine natural products^{39,40}, we have been interested in studying the anticancer activity of analogs of zyzzyanones, tsitsikammamines and wakayin. We report herein a facile synthesis of bispyrroloquinone ring system present in zyzzyanones and bispyrroloiminoquinone ring system present in wakayin and tsitsikammamines (Fig. 2).

Synthesis of bispyrroloquinone ring system (**4**) is outlined in Scheme 1. The synthesis started with the previously reported *N*-tosyl-6-(benzylamino)-1*H*-indole-4,7-dione (**6**)⁴¹. Treatment of compound **6** with ethyl acetoacetate (**7a**) in the presence of ceric ammonium nitrate (CAN) in MeOH/CH₂Cl₂ resulted in the formation of bispyrroloquinone derivative **8a** in 58 % yield. The reaction was also carried out with 1-phenylbutane-1,3-dione (**7b**) under the same reaction conditions to afford bispyrroloquinone derivative **8b** in 67 % yield. This cyclization reaction proceeds via an oxidative free radical mechanism as reported previously in the cases of aminoquinones like 2-amino-1,4-benzoquinones⁴² and 2-amino-1,4-naphoquinones^{43,44}. Tosyl groups present in compounds **8a** and **8b** were removed by treatment with NaOEt in anhydrous EtOH to form the detosylated compounds **9a** and **9b** in 71% and 86% respectively. Debenzylation of compounds **9a** and **9b** using Pd black in the presence of HCOONH₄ in anhydrous EtOH afforded the debenzylated compounds **10a** and **10b** in 75 % and 74 % yields respectively.

We employed the same synthetic methodology for the synthesis of bispyrroloiminoquinone ring system (**5**) present in wakayin and tsitsikammamines as outlined in Scheme 2.

Treatment of previously reported N-tosylpyrrolo-iminoquinone derivative, **11a**⁴⁰ with ethyl acetoacetate (**7a**) in the presence of CAN in MeOH resulted in the formation of bispyrroloiminoquinone derivative **12a** in 38 % yield. Similarly, cyclization reaction of previously reported detosylated compound **11b**⁴⁰ with ethyl acetoacetate (**7a**) in the presence of CAN in MeOH proceeded smoothly and resulted in the formation of bispyrroloiminoquinone derivative **12b** in 41 % yield.

The intermediates and final products in Scheme 1 were found to exist as a single regioisomer in each case, as evident from one set of signals found in the NMR spectra. The structure of tricyclic quinones **9a** and **9b** were further confirmed by two-dimensional NOESY experiments. The 2D NOESY experimental data for **9b** is given in Fig. 3. The three-proton singlet at 2.18 ppm is assigned to the methyl group at C-6 position. The two-proton singlet at 5.77 ppm is assigned to CH₂ group at N-7 position, which has a NOESY correlation with the singlet at 2.18 ppm. This assignment clearly shows that the more stable regioisomer **A** is formed as opposed to less stable regioisomer **B**. This is presumably be due to the steric interaction between the benzyl group at N-7 and the phenyl ring at C-6 position in **B** regioisomer.

Similarly, the products **12a** and **12b** in Scheme 2 were found to exist as a single regioisomer in each case, as evident from one set of signals found in the NMR spectra. The structure of tetracyclic quinone **12b** was also confirmed by 2D NOESY spectroscopic studies (Fig. 4). The three-proton singlet at 2.55 ppm is assigned to the methyl group on the newly formed pyrrole ring. The two-proton singlet at 5.94 ppm is assigned to the benzyl CH₂ group, which has a NOESY correlation with the singlet at 2.55 ppm. This clearly shows that the structure of **12b** is the regioisomer shown in Fig. 4.

Typical experimental procedure for the pyrrole ring formation

A solution of bicyclic quinone **6** (81 mg, 0.2 mmol) and 1-benzoylacetone **7b** (130 mg, 0.8 mmol) in a mixture of MeOH (10 mL) and CH₂Cl₂ (2mL) was stirred at room temperature for 5min. Ceric ammonium nitrate (384 mg, 0.7 mmol) was added to this reaction mixture in four portions at 10 min intervals. The reaction mixture was stirred for another 10 min at room temperature. TLC examination (hexanes/EtOAc, 1:1) revealed that the reaction was complete. Solvent was completely removed under high vacuum, and the crude product was dissolved in CH₂Cl₂ (40 mL) and washed with water (3 × 20 mL) and brine (20 mL) and dried over Na₂SO₄. The drying agent was filtered off and the solvent was concentrated in vacuo to obtain the crude product which was purified by column chromatography over silica gel (eluted with 9:1 hexanes/EtOAc) to obtain the pure tricyclic quinones **8b** in 67% yield.

In conclusion, an efficient protocol for the synthesis of the bispyrroloquinone and bispyrroloiminoquinone ring systems present in biologically active marine alkaloids such as zyzzyanones, tsitsikammamines and wakayin is reported. While this methodology does not accomplish the synthesis of these alkaloids as such, the method reported here is the first

report of the synthesis of these complex ring systems present in these alkaloids. This methodology will particularly be useful in the synthesis of various analogs of these alkaloids with specific substitution patterns. This will eventually assist in the structure activity relationship studies and optimization of the lead molecules derived from these natural products. Further studies along these lines are currently in progress.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The project described was supported by grant number 1UL1RR025777 from the NIH National Center for Research Resources. Authors also wish to acknowledge the financial support by the Breast Spore Pilot Grant and a Collaborative Programmatic Development Grant from the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center. Beginning Grant-in-Aid (AHA0865323E) from American Heart Association Greater Southeast Affiliate is also acknowledged.

References

1. Newman DJ, Cragg GM. *J Nat Prod.* 2004; 67:1216–1238. [PubMed: 15332835]
2. Haefner B. *Drug Discov Today.* 2003; 8:536–544. [PubMed: 12821301]
3. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH. *Mol Cancer Ther.* 2005; 4:333–342. [PubMed: 15713904]
4. Higa T, Tanaka J, Kitamura A, Koyama T, Takahashi M, Uchida T. *Pure Appl Chem.* 1994; 66:2227–30.
5. Sipkema D, Franssen MC, Osinga R, Tramper J, Wijffels RH. *Mar Biotechnol.* 2005; 7:142–162. [PubMed: 15776313]
6. Antunes EM, Copp BR, Davies-Coleman MT, Samaai T. *Nat Prod Rep.* 2005; 22:62–72. [PubMed: 15692617]
7. Faulkner DJ. *Nat Prod Rep.* 2002; 19:1–48. [PubMed: 11902436]
8. Dijoux MG, Gamble WR, Hallock YF, Cardellina JH, van Soest R, Boyd MR. *J Nat Prod.* 1999; 62:636–637. [PubMed: 10217730]
9. D'Ambrosio M, Guerriero A, Chiasera G, Pietra F, Tatò M. *Tetrahedron.* 1996; 52:8899–8906.
10. Chang LC, Otero-Quintero S, Hooper JN, Bewley CA. *J Nat Prod.* 2002; 65:776–778. [PubMed: 12027767]
11. Carney JR, Scheuer PJ, Kelly-Borges M. *Tetrahedron.* 1993; 49:8483–8486.
12. Casapullo A, Cutignano A, Bruno I, Bifulco G, Debitus C, Gomez-Paloma L, Riccio R. *J Nat Prod.* 2001; 64:1354–1356. [PubMed: 11678667]
13. Hu JF, Schetz JA, Kelly M, Peng JN, Ang KK, Flotow H, Leong CY, Ng SB, Buss AD, Wilkins SP, Hamann MT. *J Nat Prod.* 2002; 65:476–480. [PubMed: 11975483]
14. Radisky DC, Radisky ES, Barrows LR, Copp BR, Kramer RA, Ireland CM. *J Am Chem Soc.* 1993; 115:1632–1638.
15. Schmidt EW, Harper MK, Faulkner DJ. *J Nat Prod.* 1995; 58:1861–1867. [PubMed: 8691207]
16. Venables DA, Concepcion GP, Matsumoto SS, Barrows LR, Ireland CM. *J Nat Prod.* 1997; 60:408–410. [PubMed: 9134749]
17. Venables DA, Barrows LR, Lassota P, Ireland CM. *Tetrahedron Lett.* 1997; 38:721–722.
18. Copp BR, Ireland CM, Barrows LR. *J Org Chem.* 1991; 56:4596–4597.
19. Antunes EM, Beukes DR, Kelly M, Samaai T, Barrows LR, Marshall KM, Sincich C, Davies-Coleman MT. *J Nat Prod.* 2004; 67:1268–1276. [PubMed: 15332840]
20. Hooper GJ, Davies-Coleman MT, Kelly-Borges M, Coetzee PS. *Tetrahedron Lett.* 1996; 37:7135–7138.

21. Gunasekera SP, Zuleta IA, Longley RE, Wright AE, Pomponi SA. *J Nat Prod.* 2003; 66:1615–1617. [PubMed: 14695808]
22. Perry NB, Blunt JW, Munro MHG. *Tetrahedron.* 1988; 44:1727–1734.
23. Bénétiau V, Besson T. *Tetrahedron Lett.* 2001; 42:2673–2676.
24. Beneteau V, Pierre A, Pfeiffer B, Renard P, Besson T. *Bioorg Med Chem Lett.* 2000; 10:2231–2234. [PubMed: 11012036]
25. Kokoshka JM, Capson TL, Holden JA, Ireland CM, Barrows LR. *Anticancer Drugs.* 1996; 7:758–765. [PubMed: 8949987]
26. Legentil L, Benel L, Bertrand V, Lesur B, Delfourne E. *J Med Chem.* 2006; 49:2979–2988. [PubMed: 16686539]
27. Legentil L, Lesur B, Delfourne E. *Bioorg Med Chem Lett.* 2006; 16:427–429. [PubMed: 16242321]
28. Zhao R, Oreski B, William Lown J. *Bioorg Med Chem Lett.* 1996; 6:2169–2172.
29. Ding Q, Chichak K, Lown JW. *Curr Med Chem.* 1999; 6:1–28. [PubMed: 9873113]
30. Urban S, Hickford SJH, Blunt JW, Munro MHG. *Curr Org Chem.* 2000; 4:778–821.
31. Harayama Y, Kita Y. *Curr Org Chem.* 2005; 9:1567–1588.
32. Utkina NK, Makarchenko AE, Denisenko VA. *J Nat Prod.* 2005; 68:1424–1427. [PubMed: 16180829]
33. Utkina NK, Makarchenko AE, Denisenko VA, Dmitrenok PS. *Tetrahedron Lett.* 2004; 45:7491–7494.
34. Barret R, Roue N. *Tetrahedron Lett.* 1999; 40:3889–3890.
35. Zhang L, Cava MP, Rogers RD, Rogers LM. *Tetrahedron Lett.* 1998; 39:7677–7678.
36. Rives A, Delaine T, Legentil L, Delfourne E. *Tetrahedron Letters.* 2009; 50:1128–1130.
37. Hoang H, Huang X, Skibo EB. *Org Biomol Chem.* 2008; 6:3059–3064. [PubMed: 18698463]
38. Pringel E, Gentili J, Terreux R, Fenet B, Barret R. *Lett Org Chem.* 2005; 2:378–381.
39. Shinkre BA, Raisch KP, Fan L, Velu SE. *Bioorg Med Chem Lett.* 2007; 17:2890–2893. [PubMed: 17368022]
40. Shinkre BA, Raisch KP, Fan L, Velu SE. *Bioorg Med Chem.* 2008; 16:2541–2549. [PubMed: 18093835]
41. Sadanandan EV, Pillai SK, Lakshmikantham MV, Billimoria AD, Culpepper JS, Cava MP. *J Org Chem.* 1995; 60:1800–1805.
42. Chuang CP, Tsai AI. *Tetrahedron.* 2007; 63:11911–11919.
43. Chen H-L, Lin C-Y, Cheng Y-C, Tsai A-I, Chuang C-P. *Synthesis.* 2005:977–985.
44. Tseng CM, Wu YL, Chuang CP. *Tetrahedron.* 2004; 60:12249–12260.

1a, Zyzzyanone A, R = CH₃
1b, Zyzzyanone B, R = H

1c, Zyzzyanone A, R = CH₃
1d, Zyzzyanone B, R = H

2a, Tsitsikammamine A, R = H
2b, Tsitsikammamine B, R = CH₃

3, Wakayin

Figure 1.
Zyzzyanones, tsitsikammamines and wakayin.

Figure 2.
Bispyrroloquinone and bispyrroloiminoquinone ring systems.

Figure 3.
Two-dimensional NOESY correlation in **9b**

Figure 4.
Two-dimensional NOESY correlation in **12b**

Scheme 1.
Synthesis of bispyrroloquinone ring system.

Scheme 2.

Synthesis of bispyrroloiminoquinone ring system.